Palisade Bio to Present Groundbreaking Research at DDW 2025

Palisade Bio to Showcase Innovative Research at DDW 2025

Palisade Bio, Inc. (Nasdaq: PALI), a biopharmaceutical company dedicated to enhancing treatment options for autoimmune and inflammatory diseases, is set to present its groundbreaking research at the reputable Digestive Disease Week (DDW) 2025. This premier event, gathering experts in gastroenterology, will take place in early May.

Highlighting PALI-2108's Potential

Palisade Bio’s lead project, PALI-2108, a colon-specific PDE4 inhibitor prodrug, is generating interest within the scientific community. The company has received special recognition for its exciting research, which will be highlighted during poster presentations at the conference. Notably, one abstract from Palisade Bio was ranked in the top 10% of all submissions to the American Gastroenterological Association (AGA). This accomplishment reflects the significance of their findings in the realm of gastroenterology.

Details of the Poster Presentations

During DDW 2025, Palisade Bio will participate in two essential poster presentations showcasing the efficacy and potential of PALI-2108:

• Poster Presentation: The session titled "Transcriptional, Epigenetic and Genetic Regulation of GI Function and Disease" will occur on May 4, featuring the title "A Bioinformatic Approach to PALI-2108 Treatment in Ulcerative Colitis Reveals the Potential for Anti-Fibrotic Efficacy with Local PDE4 Inhibition in Intestinal Fibrosis." This research explores the promising anti-fibrotic effects of PALI-2108.
• DDW Poster of Distinction: On May 5, Palisade Bio will present in the "In Vivo Models of Gastrointestinal Disorders" session. The title "PALI-2108, a Colon-Specific PDE4 Inhibitor Prodrug, Is Bioactivated in the Colon and Reduces Colon Tissue PDE4B in a Dose-Dependent Manner, Increasing cAMP and Suppressing TNF-? in a Mouse Model of Colitis" showcases the prodrug's significant effects.

The Significance of Digestive Disease Week

DDW is recognized globally as a leading forum for professionals in gastroenterology. It serves as an ideal platform for leading researchers, clinicians, and pharmaceutical industry leaders to share insights and advancements in the treatment of digestive diseases. The notable presence of Palisade Bio highlights the company’s commitment to making strides in this important field of medicine.

About Palisade Bio

Palisade Bio focuses on creating innovative therapeutics with a targeted approach aimed at improving the lives of patients suffering from autoimmune, inflammatory, and fibrotic diseases. Their strategic research endeavors are designed to revolutionize therapeutic treatments and bolster the healthcare landscape. As the company progresses, it aspires to make significant changes in the treatment of chronic conditions that affect many individuals.

Conclusion

The forthcoming presentations at DDW 2025 mark a significant milestone for Palisade Bio as they continue to advance their research and development efforts. The company is poised to influence the future of treatments for ulcerative colitis and related inflammatory disorders, and the outcomes from these sessions may play a crucial role in their path forward.

Frequently Asked Questions

What is DDW?

Digestive Disease Week (DDW) is a premier event that convenes experts in gastroenterology to discuss the latest research and innovative treatments.

What is PALI-2108?

PALI-2108 is a colon-specific PDE4 inhibitor prodrug developed by Palisade Bio aimed at treating ulcerative colitis and other fibrotic conditions.

How is PALI-2108 being recognized at DDW 2025?

Palisade Bio's research on PALI-2108 has received special recognition, with one of its abstracts selected as a Poster of Distinction.

What are the potential benefits of PALI-2108?

PALI-2108 has shown promise in improving treatment outcomes for patients with ulcerative colitis, particularly through anti-fibrotic efficacy.

How can I learn more about Palisade Bio?

You can visit their official website, www.palisadebio.com, for detailed information on their research, products, and developments.

About The Author

Olivia Taylor here, a 26-year-old writer and financial advisor. After earning a degree in finance, I worked in the sector for years. I've always loved numbers and had a talent for simplifying difficult financial ideas so that anyone could understand. I wrote my first book because of this passion; it helps readers take charge of their financial futures by fusing real-life stories with useful financial advice.

Whether they are just beginning their careers, preparing for significant life events, or seeking to invest wisely, my goal with my writing is to enable people to make educated financial decisions. The foundation of my work is the conviction that security and freedom of the individual are largely determined by financial literacy. To further financial education, I run workshops and frequently write for financial blogs in addition to my books.

I like to travel, experience other cultures, and find inspiration in daily life when I'm not writing or examining market trends. My passion is utilizing sound financial practices to help people reach their financial objectives and lead the best lives possible.

Contact Olivia Taylor privately here. Or send an email with ATTN: Olivia Taylor as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.